文献速递艾滋病与性传播感染

经改良安卡拉痘苗病毒载体递送的马赛克HIV-1免疫原首次人体随机对照试验

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
PubMed 文献 · J Infect Dis · 2018-01-01

这项1期双盲随机安慰剂对照试验在健康HIV未感染成人中评估经改良安卡拉痘苗病毒(MVA)载体递送的马赛克HIV-1免疫原的安全性及免疫原性,于第0天和第84天接种2剂。全部50剂计划接种均完成,无疫苗相关严重不良事件,所有HIV-1疫苗初治参与者均诱导出交叉亚型细胞和体液免疫应答。

要点

  • 全部50剂计划接种均完成,无疫苗相关严重不良事件。
  • HIV-1疫苗初治组所有参与者接种1或2剂后均诱导出交叉亚型细胞和体液免疫应答。
  • 既往接种Ad26.ENVA.01者中几乎所有人在单次免疫后即诱导出Env特异性应答。

核心结论

  • 未发现安全性问题,并诱导出多亚型HIV-1特异性免疫应答。

研究设计与样本

  • 1期双盲随机安慰剂对照试验,入组健康HIV未感染成人。
  • 参与者于第0天和第84天接种2剂MVA载体HIV-1双价马赛克免疫原疫苗或安慰剂。
  • 入组两组:HIV-1疫苗初治者(n=15)和4-6年前曾接种HIV-1疫苗(Ad26.ENVA.01)者(n=10)。
  • 在第0、14、28、84、98、112、168、270和365天进行预设盲法细胞和体液免疫原性分析。

主要发现

  • 全部50剂计划接种均完成。
  • 接种安全且总体耐受良好,无疫苗相关严重不良事件。
  • HIV-1疫苗初治组所有参与者接种1或2剂后均诱导出交叉亚型细胞和体液免疫应答。
  • 既往接种Ad26.ENVA.01者中几乎所有人在单次免疫后即诱导出Env特异性应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mosaic immunogens are bioinformatically engineered human immunodeficiency virus type 1 (HIV-1) sequences designed to elicit clade-independent coverage against globally circulating HIV-1 strains. METHODS: This phase 1, double-blinded, randomized, placebo-controlled trial enrolled healthy HIV-uninfected adults who received 2 doses of a modified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine or placebo on days 0 and 84. Two groups were enrolled: those who were HIV-1 vaccine naive (n = 15) and those who had received an HIV-1 vaccine (Ad26.ENVA.01) 4-6 years earlier (n = 10). We performed prespecified blinded cellular and humoral immunogenicity analyses at days 0, 14, 28, 84, 98, 112, 168, 270, and 365. RESULTS: All 50 planned vaccinations were administered. Vaccination was safe and generally well tolerated. No vaccine-related serious adverse events occurred. Both cellular and humoral cross-clade immune responses were elicited after 1 or 2 vaccinations in all participants in the HIV-1 vaccine-naive group. Env-specific responses were induced after a single immunization in nearly all subjects who had previously received the prototype Ad26.ENVA.01 vaccine. CONCLUSIONS: No safety concerns were identified, and multiclade HIV-1-specific immune responses were elicited. CLINICAL TRIALS REGISTRATION: NCT02218125.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Baden LR, Walsh SR, Seaman MS, et al. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018. PMID: 29669026. doi:10.1093/infdis/jiy212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。